LWLouis M. Weiner

Louis M. Weiner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Louis M. Weiner has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effective targeting of tumor vasculature with an antibody against tumor endothelial marker 7-R (TEM7R).

    by M. Liu, J. Zhang, C. Shaller, H. Simmons, C. Bingham, M. K. Robinson, G. Adams, L. M. Weiner, H. Borghaei

    E13040 Background: Tumor associated blood vessels offer numerous tumor specific targets for therapy. St. Croix and colleagues reported the existence of novel genes expressed in human and murine tumor endothelium1,2. We report on the isolation, production and characterization of a single chain (scFv) and its corresponding IgG1 monoclonal antibody specific for murine TEM7R (mTEM7R) and present preliminary data that this antibody cross reacts with human TEM7R (hTEM7R). Methods: The cDNA encoding the extracellular domain (ECD) of mTEM7R was amplified by RT-PCR, cloned into the pSecTag2/Hygro A vector (Invitrogen) and stably transfected into HEK293 cells. A naïve human scFv phage display library comprised of 1010 independent clones3 was used to isolate scFv molecules reactive with mTEM7R. Using a solid phase panning strategy,4 we identified 5 families of anti-TEM7R scFv based on fingerprint analysis. Of the 5 families of scFv, 2 specifically bound to the mTEM7R ECD as confirmed by surface plasmon resonance (SPR) and by ELISA. One clone exhibited moderate affinity for purified ECD (10-8M) as measured by SPR and was chosen for further studies. This scFv was converted into a human IgG1 format by subcloning its Vh and Vl domains into the pMAZ-VH and pMAZ-Vl vectors (gift of Dr. Benhar, Tel-Aviv University), respectively. The resulting plasmids were co-transfected into HEK-T cells and the resulting IgG (BB1) was purified by Protein A affinity chromatography. Results: As measured by biodistribution and immuno-PET imaging studies, BB1 antibody demonstrated significant tumor uptake and prolonged tumor retention in SCID mice harboring s.c. tumor xenografts derived from five tumor cell lines of varying origin. Consistent with mTEM7R’s predicted vascular distribution, IHC and IF performed on fresh-frozen A431-derived tumor xenografts showed co-localization of BB1 and anti-CD31 antibodies to the tumor vasculature. In addition, BB1 demonstrated in vivo therapeutic efficacy against F9 (murine teratocarcinoma) and A431 tumor xenografts. Conclusions: The combined tumor targeting and therapeutic efficacy of BB1 antibody suggests TEM7R is a promising tumor vascular target and should be further investigated.

  • Fibroblast activation protein and focal adhesion kinase: novel stromal therapeutic targets in pancreatic adenocarcinoma

    by S. J. Cohen, I. Palazzo, N. J. Meropol, A. Rogatko, L. M. Weiner, E. A. Golemis, J. D. Cheng, R. K. Alpaugh

    4094 Background: Fibroblast activation protein (FAP) is a serine protease expressed on tumor stromal fibroblasts which results in tumor growth potentiation. Focal adhesion kinase (FAK) is a protein tyrosine kinase which promotes cell growth and migration through the extracellular matrix. Given the extensive desmoplasia characteristic of pancreatic adenocarcinoma, we hypothesized that FAP and FAK would be overexpressed in pancreatic cancer and contribute to poor outcome. Methods: Twenty-nine paraffin-embedded pancreatic adenocarcinoma specimens from patients undergoing curative resection were obtained from the Fox Chase Cancer Center tumor bank. Four samples (2 normal and 2 mucinous borderline tumors) served as controls. FAP and FAK expression was assessed by immunohistochemistry and graded by staining extent (%) and intensity (0–3+). Results: Ninety percent of tumor specimens (26/29) expressed FAP in either fibroblasts surrounding tumor (FST), surrounding stroma (SS), or tumor. The highest expression level by intensity was: 3+ (14), 2+ (9), 1+ (3). A strong correlation was noted between FAP expression in FST and in SS (Pearson correlation coefficient 0.75, p<0.001). In contrast, control samples displayed no FAP expression in SS. FAK was expressed on tumor cells in all 29 samples, with three-quarters having 100% staining. In addition, median FAK expression in SS was 50%. A strong correlation was noted between percent staining of FAP and FAK in SS (Pearson correlation coefficient 0.637 (p<0.001). Conclusions: FAP is overexpressed in 90% of pancreatic adenocarcinoma specimens, with similar expression in both FST and SS. FAK is also overexpressed in SS and correlates with expression of FAP, suggesting that interaction between these proteins may contribute to pancreatic cancer invasiveness. Additional samples are being evaluated and correlation with clinical characteristics is ongoing. As targeting of FAP appears promising in preclinical models, pancreatic cancer is an excellent disease for future clinical development of stromal-directed therapeutics. No significant financial relationships to disclose.


  • The rollercoaster ride to anti-cancer antibodies

    by Louis M. Weiner, Paul Carter


    • 15 June 2001
      • Vol. 61  (12) , 4750-5

    High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

    by G P Adams, R Schier, A M McCall, H H Simmons, E M Horak, R K Alpaugh, J D Marks, L M Weiner

    Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve durable tumor retention. This has spurred efforts to generate high affinity antibodies for use in cancer therapy. However, it has been hypothesized that very high affinity interactions between antibodies and tumor antigens may impair efficient tumor penetration of the monoclonal antibodies and thus diminish effective in vivo targeting (K. Fujimori et al., J. Nucl. Med., 31: 1191-1198, 1990). Here we show that intrinsic affinity properties regulate the quantitative delivery of antitumor single-chain Fv (scFv) molecules to solid tumors and the penetration of scFv from the vasculature into tumor masses. In biodistribution studies examining a series of radioiodinated scFv mutants with affinities ranging from 10(-7)-10(-11) M, quantitative tumor retention did not significantly increase with enhancements in affinity beyond 10(-9) M. Similar distribution patterns were observed when the scFv were evaluated in the absence of renal clearance in anephric mice, indicating that the rapid renal clearance of the scFv was not responsible for these observations. IHC and IF evaluations of tumor sections after the i.v. administration of scFv affinity mutants revealed that the lowest affinity molecule exhibited diffuse tumor staining whereas the highest affinity scFv was primarily retained in the perivascular regions of the tumor. These results indicate that antibody-based molecules with extremely high affinity have impaired tumor penetration properties that must be considered in the design of antibody-based cancer therapies.


    • 15 November 2000
      • Vol. 60  (22) , 6434-40

    Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

    by U B Nielsen, G P Adams, L M Weiner, J D Marks

    In immunodeficient mice antitumor single-chain Fv (scFv) molecules penetrate tumors rapidly and have rapid serum clearance, leading to excellent tumor:normal organ ratios. However, the absolute quantity of scFv retained in the tumor is low due to rapid serum clearance and monovalent scFv binding. We previously demonstrated that the presence of an additional binding site prolongs in vitro and in vivo association of scFv-based molecules with tumor cells expressing relevant antigen. The contribution of the intrinsic affinity of each component scFv to the association between a dimeric scFv and its target antigen is largely unknown. Here, we have constructed bivalent diabody molecules from three affinity mutants of the human anti-ErbB2 (HER2/neu) scFv molecule C6.5 by shortening the peptide linker between the heavy (VH) and light (VL) chains variable domains from 15 to 5 amino acids. The shorter linker prevents intramolecular pairing of VH and VL, resulting in intermolecular pairing and creation of a dimeric Mr 50,000 molecule with two antigen-binding sites. The scFv used to create the diabodies span a 133-fold range of affinity for the same epitope of ErbB2 [133 nM (C6G98A), 25 nM (C6.5), and 1 nM (C6ML3-9)] and differ by only one to three amino acids. Diabody binding kinetics were determined by surface plasmon resonance on the immobilized ErbB2 extracellular domain. The association rate constants obtained for each diabody molecule were similar to that of the parental (component) scFv. However, the dissociation rate constants obtained for the bivalent diabodies were up to 15-fold slower. The magnitude of the decrease in the bivalent dissociation rate constant was inversely proportional to the monovalent interaction, ranging from only 3-fold for that of the C6ML3-9 diabody to 15-fold for the C6G98A diabody. This resulted in only a 22-fold difference in bivalent affinity, compared with a 133-fold difference in affinity for the respective scFv. Equilibrium-binding constants obtained by surface plasmon resonance correlated well with the equilibrium-binding constants determined in vitro on ErbB2 overexpressing cells. Biodistribution studies were performed in scid mice bearing established SKOV3 tumors. At 24 h, 3-37-fold more diabody was retained in tumor compared with the parental scFv monomers. This likely results from a higher apparent affinity, because of bivalent binding, and a slower serum clearance. Surprisingly, the differences in affinity between diabodies did not result in differences in quantitative tumor retention or tumor to blood ratios. In fact, the diabody constructed from the lowest affinity scFv exhibited the best tumor-targeting properties. We conclude that, above a threshold affinity, other factors regulate quantitative tumor retention. In addition, straightforward dimerization of a low-affinity scFv leads to significantly greater tumor localization than does exhaustive scFv affinity maturation.


    • 1 June 2000
      • Vol. 6  (6) , 2219-28

    Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.

    by M Von Mehren, P Arlen, K Y Tsang, A Rogatko, N Meropol, H S Cooper, M Davey, S McLaughlin, J Schlom, L M Weiner

    Coordinated presentation of antigen and costimulatory molecules has been shown to result in the induction of an antigen-specific T-cell response rather than the development of anergy. This study evaluated the vaccine ALVAC-CEA B7.1, a canary pox virus that has been engineered to encode the gene for the tumor-associated antigen carcinoembryonic antigen (CEA) and B7.1, a T-cell costimulatory molecule. Patients with CEA-expressing tumors were immunized with 2.5 x 10(7) (n = 3), 1.0 x 10(8) (n = 6), and 4.5 x 10(8) (n = 30) plaque-forming units intradermally every other week for 8 weeks. Patients with stable or responding disease received monthly boost injections. Biopsies of vaccine sites were obtained 48 h after vaccination to evaluate leukocytic infiltration and CEA expression. Induction of CEA-specific T-cell precursors was assessed by an ELISPOT assay looking for the production of IFN-gamma. Therapy was well tolerated, without significant toxicity attributable to vaccine. All patients had evidence of leukocytic infiltration and CEA expression in vaccine biopsy sites. Six patients with elevated serum CEA values at baseline had declines in their levels lasting 4-12 weeks. These patients all had stable disease after four vaccinations. After four vaccinations, patients who were HLA-A-2-positive demonstrated increases in their CEA-specific T-cell precursor frequencies to a CEA-A2-binding peptide from baseline. The number of prior chemotherapy regimens was inversely correlated with the ability to generate a T-cell response. ALVAC-CEA B7.1 is safe in patients with advanced, recurrent adenocarcinomas that express CEA, and it is associated with the induction of a CEA-specific T-cell response.


    • 1 February 2000
      • Vol. 6  (2) , 406-14

    Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

    by S J Knox, M L Goris, M Tempero, P L Weiden, L Gentner, H Breitz, G P Adams, D Axworthy, S Gaffigan, K Bryan, et al.

    A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin (90Y-DOTA-biotin) pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary objectives of the study were to evaluate the efficacy and safety of this therapy in patients with metastatic colon cancer. Twenty-five patients were treated with a single dose of 110 mCi/m2 (mean administered dose, 106.5 +/- 10.3 mCi/m2) of 90Y-DOTA-biotin. There were three components of the therapy. Patients first received NR-LU-10/SA on day 1. A clearing agent (biotin-galactose-human serum albumin) was administered approximately 48 h after the NR-LU-10/SA to remove residual circulating unbound NR-LU-10/SA. Lastly, 24 h after administration of clearing agent, patients received biotin-DOTA-labeled with 110 mCi/m2 90Y. All three components of the therapy were administered i.v. Both hematological and nonhematological toxicities were observed. Diarrhea was the most frequent grade 4 nonhematological toxicity (16%; with 16% grade 3 diarrhea). Hematological toxicity was less severe with 8% grade 3 and 8% grade 4 neutropenia and 8% grade 3 and 16% grade 4 thrombocytopenia. The overall response rate was 8%. Two partial responders had freedom from progression of 16 weeks. Four patients (16%) had stable disease with freedom from progression of 10-20 weeks. Despite the relatively disappointing results of this study in terms of therapeutic efficacy and toxicity, proof of principle was obtained for the pretargeting approach. In addition, valuable new information was obtained about normal tissue tolerance to low-dose-rate irradiation that will help to provide useful guidelines for future study designs.


  • Production and characterization of mice transgenic for the A and B isoforms of human FcγRIII

    by Anne R. Amoroso, R. Katherine Alpaugh, Malcolm W. Barth, Adrian M. McCall, Louis M. Weiner

    Fcγ receptor (FcγR) engagement is pivotal for many effector functions of macrophages, polymorphonuclear neutrophils (PMN), and natural killer (NK) cells. Mice transgenic for the A and B isoforms of human (h) FcγRIII on macrophages, PMN, and NK cells were constructed to permit the study of mechanisms and potential in vivo strategies to utilize the cytotoxic effector and antigen-presenting functions of cells expressing the hFcγR. The present report characterizes the phenotypic and functional expression of hFcγRIII in transgenic mice derived by crossing hFcγRIIIA and hFcγRIIIB transgenic mice. Interleukin-2 (IL-2) induces hFcγRIII expression by myeloid cells and their precursors, and these transgenic receptors promote in vitro cytotoxicity and anti-hFcγRIII antibody internalization. Splenocytes from untreated and IL-2-treated hFcγRIIIA, hFcγRIIIB, and hFcγRIIIA/B mice exhibited enhanced in vitro cytotoxicity toward HER-2/neu-overexpressing SK-OV-3 human ovarian carcinoma cells when incubated with the murine bispecific mAb 2B1, which has specificity for HER-2/neu and hFcγRIII. These results indicate that hFcγRIII transgenes are expressed on relevant murine cellular subsets, exhibit inducible up-regulation patterns similar to those seen in humans, and code for functional proteins. hFcγRIII transgenic mice exhibiting specific cellular subset expression will permit the examination of strategies designed to enhance hFcγRIII-dependent immunological effector functions and will provide a model system in which to evaluate preclinically potential candidate molecules that recognize hFcγRIII for the immunotherapy of cancer.


    • 1 August 1998
      • Vol. 4  (8) , 1903-14

    Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.

    by R K Alpaugh, J Schultz, C McAleer, B J Giantonio, R Persson, M Burnite, S E Nielsen, L Vitek, B Persson, L M Weiner

    Antibody-directed, superantigen-induced cytotoxicity has been shown to have potent in vitro and in vivo antitumor effects in preclinical models. In the present study, PNU-214565, a recombinant fusion protein consisting of the Fab of the monoclonal antibody C242 and staphylococcal enterotoxin A (SEA), was used in an escalating repeat dose Phase I clinical trial in patients with advanced gastrointestinal malignancies. A prior single-dose Phase I clinical trial had demonstrated safety at doses of 1.5 ng/kg with toxicities of fever and hypotension that were not dose related. Twenty-seven patients (age range, 36-75 years; median, 62; 14 males and 13 females; 23 colorectal and 4 pancreatic) were treated in the present study with one cycle of four consecutive daily 3-h infusions of PNU-214565 at doses of 0.15 ng/kg (n = 3); 0.5 ng/kg (n = 3), 1.5 ng/kg (n = 4), 2.75 ng/kg (n = 12), and 3.5 ng/kg (n = 5). All patients had a good performance status [Eastern Cooperative Oncology Group: PS = 0 (n = 15), PS = 1 (n = 12)]. As in the single-dose trial, fever and hypotension were the most common toxicities. Dose-limiting toxicity (DLT), consisting of transient hypotension responsive to dopamine, was experienced by one patient treated at the 2.75 ng/kg dose level. One patient with pancreatic cancer metastatic to the liver experienced a partial response of hepatic metastases with stable pancreatic head abnormalities by computed tomography scan. Further dose escalation was suspended when two patients treated in a companion repeat dose Phase I study experienced DLT at the 4 ng/kg dose level. Multiparameter analyses on all patients treated in the two companion single-dose and two-repeated-dose Phase I trials revealed that the levels of patients' pretreatment anti-SEA antibodies protected against toxicity at a given drug dose. By jointly considering weight and the baseline anti-SEA concentration in a patient, it is possible to assign a PNU-214565 dose that will induce systemic cytokine release (a surrogate test to assess for the presence of uncomplexed drug and its ability to induce systemic cellular activation) without DLT. This pharmacodynamically based dosing scheme will be tested in future repeated-dose clinical trials and will define maximally tolerated doses of this powerful new immunotherapy approach.


    • 1 February 1998
      • Vol. 58  (3) , 485-90

    Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

    by G P Adams, R Schier, K Marshall, E J Wolf, A M McCall, J D Marks, L M Weiner

    Mr 25,000 single-chain Fv (scFv) molecules are rapidly eliminated from the circulation of immunodeficient mice, yielding highly specific retention of small quantities of scFv in human tumor xenografts. We postulated that the specific retention of scFv in tumor could be enhanced by engineering significant increases in the affinity of the scFv for its target antigens. Affinity mutants of the human anti-HER2/neu (c-erbB-2) scFv C6.5 were generated by site-directed mutagenesis, which target the same antigenic epitope with a 320-fold range in affinity (3.2 x 10(-7) to 1.0 x 10(-9) M). In vitro, the Kd of each scFv correlated closely with the duration of its retention on the surface of human ovarian carcinoma SK-OV-3 cells overexpressing HER2/neu. In biodistribution studies performed in scid mice bearing established SK-OV-3 tumors, the degree and specificity of tumor localization increased significantly with increasing affinity. At 24 h after injection, tumor retention of the highest affinity scFv was 7-fold greater than that of a mutant with 320-fold lower affinity for HER2/neu. Because the rapid renal clearance of scFv may blunt the impact of improved affinity on tumor targeting, the distributions were also assayed in the absence of renal clearance (e.g., in mice rendered surgically anephric). In this model, the peak tumor retentions of the two higher affinity scFv approximated that reported previously for IgG targeting the same SK-OV-3 tumors in scid mice with intact kidneys. In contrast, the mutant with the lowest affinity for HER2/neu failed to accumulate in tumor, indicating the presence of an affinity threshold that must be exceeded for active in vivo tumor uptake. These results indicate that affinity can significantly impact the in vivo tumor-specific retention of scFv molecules.